ArticleCancer cell international2025
Autophagy-targeted intervention synergized with pegaspargase: an innovative therapeutic paradigm for pancreatic cancer.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gamabufotalin suppresses pancreatic cancer through redox-homeostasis disruption by G6PD downregulation.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pegaspargase is a pegylated asparaginase formulation used in hematological malignancies. However, its application in solid tumors is greatly limited due to inherent drug resistance nature of solid tumors. Poor prognosis and lack of effective treatment options for pancreatic cancer urgently necessitate the exploration of novel therapeutic approaches. In the present study, we analyzed pegaspargase's cytotoxicity on pancreatic cancer cells (SU.86.86 and BxPC-3) in vitro. Then we evaluated the level of autophagy and related pathway proteins during treatment. Finally, we aimed to evaluate the effect of autophagy modulator on pegaspargase efficacy both in vitro and in vivo. The results revealed that pegaspargase (4 IU/mL) decreased the viability of SU.86.86 and BxPC-3 cells and induced apoptosis rates of 28.7% and 16.9%, respectively. Pegaspargase activated autophagy and downregulated Akt/mTOR path-way. Furthermore, autophagy inhibitors increased the cytotoxicity of pegaspargase (4 IU/mL) on SU.86.86 and BxPC-3 cell lines and induced apoptosis rates of 39.9% and 21.9%, respectively. In vivo evaluation confirmed that autophagy inhibition enhanced the antitumor efficacy of pegaspargase. In conclusion, our research demonstrated that combining pegaspargase with autophagy inhibition is a promising approach in pancreatic cancer clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.